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Background: Age-related cognitive impairment is rising in prevalence but is not yet fully 
characterized in terms of its epidemiology. Here, we aimed to elucidate the role of obesity, 
diabetes and hypertension as candidate risk factors.
Methods: Original baseline data from 3 studies (OCTOPUS, DECS, SuDoCo) were obtained 
for secondary analysis of cross-sectional associations of diabetes, hypertension, blood pressure, 
obesity (body mass index [BMI] ≥30 kg/m²) and BMI with presence of cognitive impairment 
in log-binomial regression analyses. Cognitive impairment was defined as scoring more than 
2 standard deviations below controls on at least one of 5–11 cognitive tests. Underweight par-
ticipants (BMI<18.5 kg/m2) were excluded. Results were pooled across studies in fixed-effects 
inverse variance models.
Results: Analyses totaled 1545 participants with a mean age of 61 years (OCTOPUS) to 70 
years (SuDoCo). Cognitive impairment was found in 29.0% of participants in DECS, 8.2% in 
SuDoCo and 45.6% in OCTOPUS. In pooled analyses, after adjustment for age, sex, diabetes 
and hypertension, obesity was associated with a 1.29-fold increased prevalence of cognitive 
impairment (risk ratio [RR] 1.29; 95% CI 0.98, 1.72). Each 1 kg/m² increment in BMI was 
associated with 3% increased prevalence (RR 1.03; 95% CI 1.00, 1.06). None of the remaining 
risk factors were associated with impairment.
Conclusion: Our results show that older people who are obese have higher prevalence of cogni-
tive impairment compared with normal weight and overweight individuals, and independently of 
co-morbid hypertension or diabetes. Prospective studies are needed to investigate the temporal 
relationship of the association.
Keywords: obesity, body mass index, diabetes, hypertension, cognitive impairment, aging, 
cognitive epidemiology
Introduction
The metabolic syndrome and its complications threaten global health. In most countries, 
prevalence is high,1 tends to increase over time2,3 and generates huge economic costs.4 
Prevalence is largest among older age groups,5 adding to the relevance of the syndrome 
as a candidate predictor of and potentially causal contributor to age-related disease 
including cognitive impairment, which itself is rising in prevalence due to globally 
ageing societies.6 It has been estimated that 22% of people aged over 70 years in the 
USA are currently cognitively impaired,7 and epidemiological studies have frequently 
demonstrated associations with the metabolic syndrome.8–13 Diabetes, hypertension and 
obesity together contribute to the diagnostic criteria of the metabolic syndrome14 and 
have each been assessed in detail for their relationship with cognitive outcome. Links 
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of diabetes to presence and risk of future cognitive impair-
ment are well established,15,16 while the evidence is less clear 
for obesity and hypertension. Here, the direction of associa-
tions appears to be dependent on the point of measurement 
during the lifespan. Whereas in prospective investigations 
spanning decades, midlife obesity and midlife hypertension 
increase the risk of later impairment,17,18 cross-sectional and 
prospective investigations with shorter follow-up periods 
have produced mixed results: late-life obesity and hyperten-
sion have each been associated with an increased13,19–22 but 
also with a reduced risk of impairment17,23–26 in those types 
of studies. For obesity, the analysis is further complicated 
by measurement issues of commonly assessed parameters 
such as body weight or body mass index (BMI) that do not 
capture body composition well. The roles of obesity and 
hypertension in particular thus warrant clarification. Impor-
tantly, many previous epidemiological investigations have 
also failed to consider that diabetes, obesity and hypertension 
tend to cluster in individuals and are highly correlated.14,27 
Each could therefore confound the other’s relationship with 
cognitive risk.
Here, we used data from 3 large clinical trials with detailed 
baseline cognitive and metabolic characterization to investi-
gate the relationships of obesity, hypertension and diabetes 
with presence of cognitive impairment in cross- sectional 
analyses that additionally considered potential mutual con-
founding among the metabolic risk factors. Results were 
pooled across the 3 studies for combined estimates.
Methods
study design
We analyzed baseline data from 3 randomized controlled 
trials with primary/secondary outcome post-operative cog-
nitive dysfunction (POCD) in an effectively observational, 
cross-sectional study design. All clinical and cognitive data 
were measured at pre-surgery assessment.
study populations and designs of included 
studies
Data from the Surgery Depth of Anaesthesia Cognitive 
Outcome (SuDoCo),28 Dexamethasone for Cardiac Surgery 
(DECS)29,30 and OCTOPUS studies31,32 were used. Access to 
original study data resulted from a cross-institutional col-
laboration. Study designs, inclusion criteria and recruitment 
procedures have been described in detail previously.28,30,31 
In brief, any patients with neurological deficits that did not 
allow cognitive testing were excluded in all the 3 studies. 
In SuDoCo, patients with Mini-Mental State Examination 
(MMSE) <24 were also excluded; those with diagnosed 
mental illness were additionally excluded in DECS. Each 
trial assessed the effect of an intervention (SuDoCo: monitor-
ing depth of anesthesia during non-cardiac surgery; DECS: 
dexamethasone administration versus placebo during cardiac 
surgery; OCTOPUS: on-pump versus off-pump methods for 
cardiac surgery) on POCD risk. Hence, each study admin-
istered neurocognitive assessment before and after surgery. 
For the purpose of the present cross-sectional analysis, only 
data collected at pre-surgery baseline assessment were used. 
Data from participants who completed pre-surgery cognitive 
testing were included. A total of 19 underweight patients, 
who could obscure linear associations of obesity with cogni-
tive impairment, and patients with missing data on diabetes, 
hypertension and obesity were excluded from our analyses.
Physical examination and education
In each study, detailed physical examination and self-
reported medical history were used to identify participants 
with any type of diabetes and those with a history of hyper-
tension. BMI was calculated from participants’ height and 
weight. “Obesity” was defined as BMI of at least 30 kg/
m2. “Underweight” was defined as BMI <18.5 kg/m². In 
OCTOPUS and SuDoCo, blood pressure was measured 
at pre-anesthetic assessment during the days prior to sur-
gery. Blood pressure data were not available for DECS. 
Participants self-reported on their level of education in 
OCTOPUS and DECS; data on education were not avail-
able for SuDoCo. 
Cognitive examination
Trained staff preoperatively administered 11 neuropsycho-
logical tests in OCTOPUS, 5 neuropsychological tests in 
DECS and 6 neuropsychological tests in SuDoCo. In each 
of the 3 studies, all tests were additionally completed by 
non-surgical control groups to provide normative data. The 
respective control groups were matched for age (OCTO-
PUS), age and sex (DECS), or age and cognitive function 
(SuDoCo) and had been recruited at a cardiology outpatient 
clinic (DECS30), or in nursing homes and senior citizen clubs 
(SuDoCo28). For OCTOPUS, healthy volunteers served as 
controls.33 All neuropsychological tests were age sensitive 
and covered a range of neurocognitive domains including 
working memory, attention, processing speed, manual dexter-
ity, executive function and mental flexibility. In OCTOPUS, 
paper-pencil versions of the Rey Auditory Verbal Learning 
Test, Grooved Pegboard Test, Subjective Ordering Task, 
Sternberg Letter Cancellation Task, Trail-Making Test B, 
Stroop-Color-Word-Test and Symbol Digit Modalities Task 
were applied. For DECS, paper-pencil versions of the Rey 
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Auditory Verbal Learning Test, Grooved Pegboard Test, Corsi 
Blocks, Wechsler Adult Intelligence Scale-Digit Span, Trail-
Making Test A and B were used. The SuDoCo trial covered 
the Motor Screening Test, Pattern Recognition Memory, 
Spatial Recognition Memory and Choice Reaction Time tests 
from the CANTAB computerized test battery as well as the 
paper-pencil based Stroop Color and Word Test and visual 
Verbal Learning Test.
We first excluded patients with missing cognitive data 
and performed an outlier correction for extreme values in 
individual test parameters. Using the respective interquar-
tile range of test scores, 8 out of 2176 single test scores in 
OCTOPUS and 92 out of 15015 single test scores in SuDoCo 
were excluded, but no single patient had to be excluded in 
total due to this outlier correction. There were no outliers 
to be removed in DECS. Presence of cognitive impairment 
was then defined as scores of more than 2 SDs below the 
respective control group on ≥1 test.34
statistical analysis
Multiple log-binomial regression analyses determined 
associations of each of the parameters of metabolic function 
(diabetes, obesity, BMI, hypertension, systolic and diastolic 
blood pressure) with presence of cognitive impairment. The 
first model estimated unadjusted risk (prevalence) ratios 
(RRs) (model 0). Age and sex were entered as covariables 
in model 1. Model 2 additionally controlled for the respec-
tive remaining potential metabolic risk factors (e.g., analy-
ses of obesity, hypertension and diabetes were controlled 
for) in order to evaluate independence of any associations 
from comorbidity with other components of the metabolic 
syndrome versus mutual confounding. For 2 of the studies 
(OCTOPUS; DECS), data on educational level of participants 
were available; thus, education was additionally adjusted for 
in a final step (model 3). Estimated risk ratios corresponded to 
1-point increments in BMI and 10-point increments in blood 
pressure values to aid clinical interpretability.
Analyses were performed separately for each of the 3 
studies and were then pooled in fixed-effects inverse vari-
ance analyses for each of the metabolic parameters. Model 
estimates of risk ratios and corresponding p-values were 
entered with precision up to the third decimal, and 95% CIs 
were entered with precision up to the first decimal point. 
Fixed-effects models were selected on the basis that the same 
effect was assumed to underlie estimates in all the 3 studies.35 
Fully adjusted models (model 2) were repeated using random-
effects models to show the mean distribution of effects (Table 
S1). The I2 index determined the proportion of variance 
between the 3 studies that would remain had we removed 
sampling error. These pooled analyses were  necessary to 
combine risk estimates across all 1545 participants of the 3 
studies and so should not be understood as a meta-analysis of 
previous research. The statistical analysis plan was approved 
by an internal committee before the analyses were performed 
in IBM© SPSS© Statistics ( version 24), The R Project for 
Statistical Computing ( version 3.3.3) and Review Manager 
(version 5.3).
Ethics
Participants of all the studies gave written informed consent 
upon enrollment. Ethical approval was obtained for each of 
the studies and assessments complied with the Declaration 
of Helsinki. For the present secondary analysis, additional 
ethical approval was obtained (Ethikkommission der Charité 
– Universitätsmedizin Berlin, EA1/242/08).
Results
Metabolic and cognitive characterization 
of study samples
Analyses were based on N=272 patients from DECS, N=272 
patients from OCTOPUS and N=1001 patients from SuDoCo 
(Figure S1). Participant characteristics for each of the 3 stud-
ies are summarized in Table 1. Mean sample age ranged from 
61 years (OCTOPUS) to 70 years (SuDoCo). Reasons for 
surgery were severe cardiac disease in DECS and OCTOPUS; 
patients in SuDoCo underwent any non-cardiac surgery 
mainly of general surgery, orthopedic or gynecological/
urological type. Mean BMI was in the overweight category 
in each of the 3 studies (BMI ≥25 kg/m2), with prevalence of 
obesity (BMI ≥30 kg/m2) ranging between 14.7% (OCTO-
PUS) and 24.0% (SuDoCo). Cognitive impairment was iden-
tified in 8.2% (SuDoCo) to 45.6% (OCTOPUS) of patients. 
Across all the 3 studies, 285 (18.4%) of 1545 patients had 
cognitive impairment.
associations of metabolic syndrome 
parameters with cognitive impairment
Associations of diabetes, hypertension and obesity with cog-
nitive impairment are shown in Table 2. In pooled analyses, 
obesity was associated with presence of cognitive impairment 
and independently of age, sex, diabetes or hypertension. 
Obese participants were overall 1.29-fold more likely to pres-
ent with cognitive impairment compared with normal weight 
and overweight individuals (RR 1.29; 95% CI 0.98, 1.72) 
with no evidence of statistical heterogeneity among the stud-
ies (Chi2=0.55; I2=0%; Table 2; Figure 1). Similar findings 
were observed with further adjustment for educational level 
(RR 1.33; 95% CI 0.94, 1.87). Diabetes and  hypertension 
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Table 1 sample characteristics of the 3 studies
Sample characteristics OCTOPUS DECS SuDoCo
Country The netherlands The netherlands germany
n 272 272 1001
age, years, mean ± sD 61.4 ± 9.1 64.1 ± 11.9 69.9 ± 6.5
Male, n (%) 189 (69.5%) 210 (77.2%) 556 (55.5%)
Education, mean ± sD years, or n (%) 9.4 ± 2.6 Primary: n=119 (43.8%)
secondary: n=70 (25.7%)
Further/higher: n=83 (30.5%)
–
systolic blood pressure, mmhg, mean ± sD 138.9 ± 19.6 – 136.3 ± 19.3 
Diastolic blood pressure, mmhg, mean ± sD 79.2 ± 10.0 – 73.9 ± 11.6
Diabetes, n (%) 35 (12.9%) 44 (16.2%) 215 (21.5%)
hypertension, n (%) 112 (41.2%) 150 (55.1%) 683 (68.2%)
Body mass index (kg/m2) mean ± sD 26.6 ± 3.1 27.2 ± 4.5 27.4 ± 5.0
normal weight (BMi 18.5 to 24.9) n (%) 
Overweight (BMi 25.0 to 29.9) n (%) 
Class i obesity (BMi 30 to 34.9) n (%)  
Class ii obesity (BMi 35.0 to 39.9) n (%)
Class iii obesity (BMi ≥40) n (%)
94 (34.6%) 
138 (50.7%) 
40 (14.7%)
99 (36.4%) 
114 (41.9%) 
45 (16.5%) 
9 (3.3%) 
5 (1.8%)
326 (32.6%) 
435 (43.5%) 
166 (16.6%) 
49 (4.9%) 
25 (2.5%)
Cognitive impairment, n (%) 124 (45.6%) 79 (29.0%) 82 (8.2%)
Note: Data on systolic and diastolic blood pressure available for n=270 in OCTOPUs and n=949 in suDoCo. % shown of total sample. surgical procedures were cardiac 
surgery (OCTOPUs, DECs) or general surgery (suDoCo). BMi ≥30 kg/m² was used as cutoff for subgroup analyses on obesity. Different sets of cognitive tests were used 
in each of the studies (see Methods).
Abbreviations: BMi, body mass index; DECs, Dexamethasone for Cardiac surgery; sD, standard deviation; suDoCo, surgery Depth of anaesthesia Cognitive Outcome.
Table 2 association of diabetes, hypertension, and obesity with cognitive impairment in each study, and pooled estimates of prevalence 
ratios
Exposure associations 
with cognitive 
impairment
OCTOPUS DECS SuDoCo Pooled 
estimates
Estimate (95% Ci) Weight Estimate (95% Ci) Weight Estimate (95% Ci) Weight Estimate (95% Ci)
Diabetes and cognitive impairment
Model 0: no adjustment 0.93 (0.59, 1.34) 38.1% 1.53 (0.97, 2.25) 34.8% 1.18 (0.71, 1.87) 27.1% 1.18 (0.92, 1.52)
Model 1: age, sex 0.82 (0.46, 1.37) 25.1% 1.46 (0.93, 2.16) 42.5% 1.21 (0.73, 1.91)  32.4% 1.19 (0.91, 1.56)
Model 2: +hypertension, 
obesity
0.77 (0.43, 1.31) 30.5% 1.35 (0.76, 2.30) 31.6% 1.20 (0.71, 1.95) 37.9% 1.09 (0.80, 1.49)
Model 3: +education 0.92 (0.50, 1.57) 47.9% 1.39 (0.79, 2.35)  52.1% – – 1.14 (0.77, 1.69)
hypertension and cognitive impairment
Model 0: no adjustment 1.22 (0.94, 1.57)  56.0% 1.13 (0.78, 1.67)  26.0% 1.06 (0.69, 1.70) 18.1% 1.16 (0.96, 1.41)
Model 1: age, sex 1.08 (0.75, 1.55) 39.5% 1.06 (0.73, 1.58)  35.4% 0.98 (0.63, 1.57) 25.1% 1.05 (0.83, 1.32)
Model 2: +diabetes, obesity 1.10 (0.76, 1.59) 44.8% 0.95 (0.60, 1.53) 27.9% 0.91 (0.57, 1.49) 27.3% 1.00 (0.78, 1.28)
Model 3: +education 1.07 (0.74, 1.56) 60.6% 1.01 (0.64, 1.62) 39.4% – – 1.05 (0.78, 1.40)
Obesity and cognitive impairment
Model 0: no adjustment 1.25 (0.88, 1.67) 47.2% 1.58 (1.05, 2.28) 32.1% 1.09 (0.66, 1.72) 20.8% 1.31 (1.05, 1.63)
Model 1: age, sex 1.26 (0.77, 1.96) 29.4% 1.56 (1.04, 2.26) 42.5% 1.16 (0.70, 1.83) 28.1% 1.35 (1.05, 1.73)
Model 2: +diabetes, 
hypertension
1.28 (0.78, 2.00) 36.3% 1.49 (0.89, 2.45) 31.3% 1.14 (0.68, 1.85) 32.4% 1.29 (0.98, 1.72)
Model 3: +education 1.29 (0.79, 2.02) 53.4% 1.38 (0.82, 2.25) 46.6% – – 1.33 (0.94, 1.87)
Note: results from log-binomial regression analyses. For each study, results for Model 2 and Model 3 are based on a single model respectively. 
Abbreviations: CI, confidence interval; DECS, Dexamethasone for Cardiac Surgery; RR, risk ratio; SuDoCo, Surgery Depth of Anaesthesia Cognitive Outcome.
were not associated with cognitive impairment in any of the 
studies or in pooled analyses (Table 2).
Associations of BMI and blood pressure with cognitive 
impairment are shown in Table 3. A higher BMI was asso-
ciated with an increased prevalence of impairment across 
studies. Independently of age, sex, diabetes and hyperten-
sion, each one unit increment in BMI was associated with a 
3% increased prevalence of cognitive impairment (RR 1.03; 
95% CI 1.00, 1.06). There was no evidence of statistical 
heterogeneity among the studies (Chi2=0.50; I2=0%; Table 3; 
 Figure 2), and the finding remained similar following addi-
tional adjustment for education (RR 1.03; 95% CI 0.99, 1.07). 
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Figure 1 Pooled association of obesity with cognitive impairment (model 2).
Abbreviations: CI, confidence interval; DECS, Dexamethasone for Cardiac Surgery; SE, standard error; SuDoCo, Surgery Depth of Anaesthesia Cognitive Outcome.
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Test for overall effect: Z = 1.79 (P = 0.07)
Heterogeneity: χ2 = 0.55, df = 2 (P = 0.76); I2 = 0%
Table 3 association of BMi, systolic and diastolic blood pressure with cognitive impairment in each study, and pooled estimates of 
prevalence ratios
OCTOPUS DECS SuDoCo Pooled 
estimates
Estimate 
(95% CI)
Weight Estimate
(95% CI)
Weight Estimate 
(95% CI)
Weight Estimate 
(95% CI)
BMi and cognitive impairment
Model 0: no adjustment 1.02 (0.97, 1.06) 35.5% 1.04 (1.00, 1.09) 31.2% 1.01 (0.97, 1.05) 33.3% 1.02 (1.00, 1.05)
Model 1: age, sex 1.02 (0.96, 1.08) 22.6% 1.04 (1.00, 1.09) 38.0% 1.02 (0.97, 1.06) 39.4% 1.03 (1.00, 1.06)
Model 2: +diabetes, 
hypertension
1.02 (0.96, 1.08) 24.3% 1.04 (0.99, 1.09) 37.0% 1.02 (0.97, 1.06) 38.6% 1.03 (1.00, 1.06)
Model 3: +education 1.02 (0.97, 1.09) 38.7% 1.03 (0.98, 1.08) 61.3% – – 1.03 (0.99, 1.07)
systolic blood pressure and cognitive impairment
Model 0: no adjustment 0.98 (0.89, 1.07) 61.4% – – 1.03 (0.91, 1.14) 38.6% 0.99 (0.93, 1.07)
Model 1: age, sex 0.94 (0.85, 1.03) 64.9% – – 1.01 (0.89, 1.12) 35.1% 0.96 (0.89, 1.03)
Model 2: +diabetes, obesity 0.94 (0.85, 1.03) 60.7% – – 1.00 (0.89, 1.12) 39.3% 0.96 (0.89, 1.03)
Model 3: +education 0.95 (0.86, 1.04) – – – – – –
Diastolic blood pressure and cognitive impairment
Model 0: no adjustment 0.86 (0.72, 1.03)  54.1% – – 0.96 (0.79, 1.17) 45.9% 0.90 (0.79, 1.03)
Model 1: age, sex 0.89 (0.74, 1.07) 52.1% – – 0.98 (0.81, 1.19) 47.9% 0.93 (0.81, 1.06)
Model 2: +diabetes, obesity 0.89 (0.74, 1.07) 53.2% – – 0.98 (0.81, 1.18) 46.8% 0.93 (0.81, 1.07)
Model 3: +education 0.90 (0.75, 1.08) – – – – – –
Note: results from log-binomial regression analyses. Estimates correspond to 1 kg/m2 increment in BMi and 10 mmhg increment in blood pressure. Data on systolic/diastolic 
blood pressure available for n=270 participants in OCTOPUs and for n=949 participants in suDoCo. Data on blood pressure not available for DECs. For each study, results 
for Model 2 and Model 3 are based on a single model respectively. 
Abbreviations: BMI, body mass index; CI, confidence interval; DECS, Dexamethasone for Cardiac Surgery; RR, risk ratios; SuDoCo, Surgery Depth of Anaesthesia Cognitive 
Outcome.
Figure 2 Pooled association of BMi with cognitive impairment (model 2).
Abbreviations: BMI, body mass index; CI, confidence interval; DECS, Dexamethasone for Cardiac Surgery; SE, standard error; SuDoCo, Surgery Depth of Anaesthesia 
Cognitive Outcome.
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In a post hoc analysis to further elucidate the  relationship of 
BMI and cognitive impairment, model 2 (controlling for age, 
sex, diabetes, hypertension) was repeated for the “obese” 
category (BMI ≥30 kg/m2) rather than the total sample. When 
effects were pooled across 339 obese participants in this 
subgroup, each one unit increment in BMI was associated 
with an 8% increased prevalence of cognitive impairment 
(RR 1.08; 95% CI 1.01, 1.16).
Systolic and diastolic blood pressures were not associated 
with cognitive impairment (Table 3).
Of note, there were no associations of sex with cognitive 
impairment in any of our analyses (data not shown); thus, 
sex was not further explored as a modifier of the association 
of obesity or BMI with cognitive impairment.
Discussion
In this secondary analysis of cross-sectional data from 3 
studies, prevalence of cognitive impairment as defined by 
a lower performance compared with controls was relatively 
high compared with some previous investigations.36 Over-
all, 18.4% of patients had cognitive impairment. Though 
there was substantial heterogeneity in prevalence between 
the 3 studies that ranged from 8.2% (SuDoCo) to 45.6% 
(OCTOPUS). When results were pooled across the 3 stud-
ies to assess metabolic predictors of cognitive impairment, 
we found a 29% increased prevalence of cognitive impair-
ment in participants who are obese (BMI ≥30 kg/m2) com-
pared with normal weight to overweight individuals. Each 
1 kg/m² increment of BMI was associated with 3% increased 
prevalence. That estimate even increased to 8% increased 
prevalence of impairment for each 1 kg/m2 increment of BMI 
when analyses of BMI were restricted to participants in the 
“obese” category. Overall this is suggestive of a non-linear 
dose–response relationship of BMI with impairment.
Previous epidemiological studies identified diabetes15,16 
and, although less consistently, hypertension and obesity 
measured in later life13,17,19,21,22 as risk factors for cognitive 
impairment. However, many of these studies assessed each 
of these candidate predictors in isolation or with consider-
ation of few other metabolic factors. Because all correlate 
strongly with one another,14,27 the individual contribution of 
each to cognitive outcome may have been obscured in those 
analyses. Even in cases where some of these factors have 
been controlled for, residual confounding is a real possibility.
In one of the first studies to investigate cognitive impair-
ment in later life to consider such confounding, we estab-
lished that the cross-sectional associations of obesity and 
a higher BMI with presence of cognitive impairment were 
independent of comorbid diabetes and hypertension. As we 
adjusted for 3 of 4 components of the metabolic syndrome 
(all except dyslipidemia), it follows that obesity might be one 
driving force behind the cognitive impairment seen in people 
with the metabolic syndrome.8–13 Mediation of the obesity-
cognition association by presence of diabetes or hypertension 
is unlikely, as controlling for mediating factors would have 
led to a profound reduction in effect size. However, the pos-
sibility of an influence of subclinical insulin resistance or 
subclinical elevated blood pressure remains.
Our cross-sectional data suggest that diabetes and hyper-
tension themselves are not at all or only weakly associated 
with cognitive impairment. Reasons for disparity from previ-
ous epidemiological research that had implicated hypertension 
and (even more strongly) diabetes in cognitive risk16,20 are 
unclear but may stem from the fact that 2 of our studies were 
of a high-risk (rather than general) population. Further, our 
definition of “cognitive impairment” may be less sensitive to 
pathological changes associated with hypertension or diabetes, 
and none of the 3 studies had set out to determine associations 
of metabolic risk factors with cognitive impairment, so that 
data on diabetes and hypertension, in contrast to measurement 
of participants’ cognitive status, height and weight, may not 
have been collected with sufficient rigor. This could have led 
to the lack of a finding on diabetes and hypertension.
Obesity – though both preventable and modifiable – is 
threatening global health through increasing risk of poor 
health outcomes. Four million deaths per year are currently 
attributed to a high BMI globally.37 In our study, we found 
that older people who were obese were more likely to be 
cognitively impaired, which highlights the relevance of 
cognitive impairment as an obesity-related organ dysfunc-
tion that is equal in importance to others such as coronary 
heart or kidney disease, for instance. With BMI as a crude 
reflection of actual body composition particularly in older 
people38,39 effect sizes could have been even larger than 
reported here had we used more detailed assessments such 
as body fat. Importantly, we found evidence for a non-linear 
dose–response relationship that suggests that cognitive 
risk increases exponentially with increasing BMI among 
people with normal weight, overweight and obesity. Our 
study lacked data on BMI change across the life span. This 
reflects one aspect that complicates research of obesity and 
cognitive outcome: unless participants are followed up 
over the course of decades,40 even studies with prospective 
designs provide only “snapshots” of adiposity status. Expo-
sure to weight change due to aging and/or disease remains 
obscure despite evidence from rare long-term prospective 
 investigations of a potential role of weight change in cogni-
tive risk prediction.24
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The pathophysiology linking obesity with cognitive 
impairment is poorly understood but may be causal. Obesity 
constitutes a pro-inflammatory state,41 which itself has been 
associated with cognitive impairment,42 and animal models 
suggest that elevated triglyceride levels which are common 
in obese individuals, impair brain function.43,44 Relatedly, 
obesity-induced systemic damage of the vasculature could 
cause cerebral white matter lesions.45 The apparent non-linear 
relationship of BMI with cognitive impairment in our analy-
sis may indicate cumulative effects of these mechanisms. 
Because the effect size of the association of obesity with 
cognitive impairment was unchanged after adjustment for 
education, it is unlikely that it was due to confounding by 
this factor that could have led to exposure of people of low 
socioeconomic status to an increased risk of both late-life 
obesity46,47 and late-life cognitive impairment.48,49 Reverse 
causality underlying our findings is also possible, however, 
due to the cross-sectional study design. Obesity following 
increased food intake50 or reduced physical activity51 might 
also be the result of beginning cognitive impairment.
We investigated several parameters of metabolic derange-
ment for their cross-sectional association with cognitive 
impairment. This enabled us to tease out the contribution of 
each to cognitive risk. We took advantage of comprehensive 
neuropsychological test batteries that tapped a range of cog-
nitive domains, and combined results across the 3 studies to 
obtain more reliable parameter estimates. 
Limitations 
Our study has several limitations. First, analyses were of 
patients scheduled to undergo surgery within the next few 
days. Cognitive performance could therefore have been 
influenced by surgery-related factors such as psychologi-
cal distress, anxiety and pain, and patients will have been 
less healthy compared with community-dwelling samples. 
This is likely reflected in the relatively high prevalence of 
cognitive impairment. At the same time, self-selection bias 
for healthier patients to enroll compared with all approached 
individuals is also likely. These factors all limit the external 
validity of our findings. Second, we pooled results across 
3 studies that were heterogeneous in terms of design and 
sample characteristics, which complicates the interpreta-
tion of our findings. For instance, 2 of the studies included 
rather sick individuals undergoing cardiac surgery, whereas 
another focused on less severe (e.g., orthopedic) procedures, 
and different cognitive test batteries each with a different 
number of tests were used in each of the 3 studies. This 
may have influenced prevalence of cognitive impairment. 
Also, readers should note that the clinical significance of 
our findings is unclear due to the definition of “cognitive 
impairment” that may have captured mild forms of impair-
ment. Third, the metabolic parameters were determined by 
single-time assessment; none of the studies prospectively 
investigated their development or change over time, and so 
we cannot draw conclusions on fluctuations in the severity 
of hypertension, diabetes or obesity and associated cognitive 
risk. Fourth, obesity was defined by BMI despite the fact 
that BMI does not capture body fat and body fat distribution 
which are likely driving forces behind obesity links to nega-
tive health outcomes.52 The use of BMI in older people for 
this purpose appears to be particularly limited.38,39 Fifth, we 
had no data on dyslipidemia to allow adjustment for the final 
component of the metabolic syndrome. Sixth, our results 
are limited by relatively large CIs of estimates due to small 
sample size. Finally, due to the cross-sectional study design 
our finding may well reflect reverse causality.
Further studies are needed to evaluate the external validity 
of our findings through replication in community-dwelling 
samples, and should examine the underlying pathophysi-
ological mechanisms as well as the influence of body weight 
trajectories over the life-course on late-life cognition. Com-
parison among various cognitive domains could determine 
any domain-specific effects of obesity. Trials modeled on the 
Action for Health in Diabetes study53 could further determine 
the influence of weight loss on cognitive outcome in different 
weight categories to determine whether weight loss effects on 
cognition, too, may be non-linear. Once the role of obesity 
in cognitive impairment is better understood, preventive 
pharmacological strategies or health programs could reduce 
cognitive risk in people who are at risk of developing obesity, 
such as overweight and physically inactive individuals.
Conclusion
Our cross-sectional analysis suggests that among high-risk 
older people who are scheduled to undergo surgery, those who 
are obese have a higher likelihood of cognitive impairment 
compared to normal weight or overweight persons. Among 
normal weight, overweight and obese persons, a higher BMI is 
associated with a higher prevalence of cognitive impairment. 
The association appears to increase in strength with increasing 
BMI. Further studies are needed to prospectively investigate 
the temporal relationship of body weight and cognitive risk.
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Supplementary materials
Table S1 Results for model 2 in fixed-effects model (as described in main manuscript) and random-effects models
Exposure associations with cognitive 
impairment
Model 2 as fixed-effects model
RR (95% CI)
Model 2 as random-effects model
RR (95% CI)
Diabetes and cognitive impairment 1.09 (0.80, 1.49) 1.09 (0.79, 1.51)
hypertension and cognitive impairment 1.00 (0.78, 1.28) 1.00 (0.78, 1.28)
Obesity and cognitive impairment 1.29 (0.98, 1.72) 1.29 (0.98, 1.72)
BMi and cognitive impairment 1.03 (1.00, 1.06) 1.03 (1.00, 1.06)
systolic blood pressure and cognitive impairment 0.96 (0.89, 1.03) 0.96 (0.89, 1.03)
Diastolic blood pressure and cognitive impairment 0.93 (0.81, 1.07) 0.93 (0.81, 1.07)
Abbreviations: BMI, body mass index; CI, confidence interval; RR, risk ratio.
Figure S1 Enrollment into the 3 studies.
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